Purpose of the Test
- Early detection of bladder cancer in high-risk individuals.
- Monitoring patients after tumor resection to detect recurrence.
- Providing complementary data to cystoscopy procedures.
Book NMP22 Bladder Test | Lahalak Medical Platform
A rapid immunoassay detecting NMP22 protein in urine, serving as a vital adjunct to cystoscopy for early bladder cancer screening and post-treatment monitoring to ensure patient safety and health.
Scientific name: Nuclear Matrix Protein 22 (NMP22) Urine Test
A laboratory test measuring NMP22 protein levels in urine. It acts as a biomarker to help detect bladder cancer cells and monitor patients post-treatment for recurrence effectively.
Service type
Laboratory test
Duration
15-20 minutes
Fasting
Fasting is not required
Included Services
- Urine sample collection
- Immunoassay lab analysis
- Results report
Medical Service Information
Target Groups
- Current and former smokers.
- Individuals experiencing blood in the urine (hematuria).
- Patients with a history of bladder cancer.
Frequently Asked Questions
- Does this test replace cystoscopy? No, it is a complementary test used alongside it.
- When will results be ready? Typically within 24 to 48 hours.
Conditions & Notices
- Morning urine sample preferred
- Inform the doctor if you have a urinary tract infection
Medical services you might also like
